Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer Released
“We are very encouraged by these results and thrilled by the signs of rapid reduction in Ki-67 and FTV as it demonstrates progress in our effort to develop (Z)-endoxifen as an effective and tolerant neoadjuvant treatment for ER+/HER2- breast cancer patients. This data provides further evidence that (Z)-endoxifen may be able to slow the progression of ER+ breast cancer in the neoadjuvant setting,” said Dr. Steven Quay, Chief Executive Officer of Atossa Therapeutics. “We are honored to have these findings from the I-SPY 2 EOP study of (Z)-endoxifen presented at the inaugural RISE UP conference and commend Dr. Laura Esserman and other members of the Organizing Committee for their focus on reimagining breast cancer prevention and treatment.”
Share:
More News
“Between 2017 and 2023, the socioeconomic burden of HER2-positive breast cancer in ten major economies was nearly $590 billion, projected to increase to nearly $1,000 billion by 2032,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At-home treatment may help alleviate the pressure
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
“Beyond the second-line monotherapy opportunity, we and our partners at Pfizer have removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan,” continued Dr. Houston. “This decision was made following
“The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.”
